Results - Announcements
Sun Pharma Advanced Research Company Ltd share price slipped 1.02% to Rs 175.1 after the company's net profit registered a growth of 17.37% to Rs 24.39 crore, while revenue from operations nosedived 24.77% to Rs 30.03 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, rising 4.75%. It has improved by 2.16% over last one week and gained upto 0.86% in last one month while the market capitalization of Sun Pharma Advanced Research Company Ltd has eased by 1.90% and 19.75% in the same period respectively.
Profit before tax (PBT) of Sun Pharma Advanced Research Company Ltd stood at Rs 24.31 crore in Q3 FY26, tumbling by 67.92% year-on-year, and expanding by 17.61% quarter-on-quarter. EBITDA came in at Rs 69 crore, gaining 5.32% YoY and rallying 20.07% sequentially.
Total expenses saw a slight increase of 2.26% to Rs 77.84 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 9.95 crore, surging by 29.90% YoY, while employee benefits expense was at Rs 29.33 crore, softening 0.95% YoY.
For the TTM ended FY26, revenue from operations plunged by 45.45% to Rs 39.15 crore, while net profit witnessed a sharp fall of 553.48% to Rs 1553.2 crore, compared to previous TTM. EBITDA tanked by 32811% to Rs 1587.81 crore, and PBT tumbled by 553.06% to Rs 1553.01 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 238.77 crore in FY26, as against Rs 360.29 crore in FY25.
Sun Pharma Advanced Research Company Ltd jumped 24.89% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 9.87% during the same period.